Titre du document / Document title

Adjunctive use of reboxetine in schizophrenia

Auteur(s) / Author(s)

RAEDLER Thomas J. ⁽¹⁾ ; JAHN Holger ⁽¹⁾ ; ARLT Josef ⁽¹⁾ ; KIEFER Falk ⁽¹⁾ ; SCHICK Mildred ⁽¹⁾ ; NABER Dieter ⁽¹⁾ ; WIEDEMANN Klaus ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martini str. 52, 20246 Hamburg, ALLEMAGNE

Résumé / Abstract

Background. - Schizophrenia is frequently complicated by depressive or negative symptoms that respond only moderately to treatment with antipsychotic drugs. Reboxetine is a novel antidepressant, which inhibits the reuptake of norepinephrine. We sought to study the efficacy and tolerability of the adjunctive use of reboxetine in a cohort of schizophrenic patients with prominent depressive or negative symptoms. Methods. - Sixteen schizophrenic inpatients were recruited for this study. All subjects received 4-8 mg of reboxetine/day while the antipsychotic medication (typical antipsychotics = 4; atypical antipsychotics = 12) was continued. All subjects underwent a standardized assessment including PANSS, CGI, HAMD, and CDSS before and after treatment with reboxetine (mean 26 ± 17 d). Results.- All subjects tolerated treatment with reboxetine. Adverse effects were mild and did not require discontinuation of reboxetine. All clinical scores (PANSS 93.1 vs. 63.1; CGI 5.4 vs. 4.1; HAMD 20.4 vs. 8.1; CDSS 12.5 vs. 4.6) improved significantly under adjunctive treatment with reboxetine (all P < 0.01). Conclusion. - The adjunctive use of reboxetine in schizophrenic patients was safe and well-tolerated. Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia.

Revue / Journal Title

European psychiatry   ISSN 0924-9338 

Source / Source

2004, vol. 19, n^o6, pp. 366-369 [4 page(s) (article)] (29 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, Paris, FRANCE  (1991) (Revue)

Mots-clés anglais / English Keywords

Norepinephrine ; Reuptake inhibitor ; Psychotropic ; Antidepressant agent ; Mood disorder ; Schizoaffective psychosis ; Psychosis ; Human ; Follow up study ; Toxicity ; Treatment efficiency ; Severity score ; Evolution ; Comparative study ; Reboxetine ; Drug combination ; Atypical ; Neuroleptic ; Chemotherapy ; Treatment ; Depression ; Negative symptom ; Symptomatology ; Schizophrenia ;

Mots-clés français / French Keywords

Noradrénaline ; Inhibiteur recapture ; Psychotrope ; Antidépresseur ; Trouble humeur ; Psychose schizoaffective ; Psychose ; Homme ; Etude longitudinale ; Toxicité ; Efficacité traitement ; Indice gravité ; Evolution ; Etude comparative ; Réboxétine ; Association médicamenteuse ; Atypique ; Neuroleptique ; Chimiothérapie ; Traitement ; Etat dépressif ; Symptôme négatif ; Symptomatologie ; Schizophrénie ;

Mots-clés espagnols / Spanish Keywords

Noradrenalina ; Inhibidor recaptura ; Psicotropo ; Antidepresor ; Trastorno humor ; Psicosis esquizoafectiva ; Psicosis ; Hombre ; Estudio longitudinal ; Toxicidad ; Eficacia tratamiento ; Indicio gravedad ; Evolución ; Estudio comparativo ; Reboxetina ; Asociación medicamentosa ; Atípico ; Neuroléptico ; Quimioterapia ; Tratamiento ; Estado depresivo ; Síntoma negativo ; Sintomatología ; Esquizofrenia ;

Mots-clés d'auteur / Author Keywords

Schizophrenia ; Depression ; Negative symptoms ; Antidepressants ; Reboxetine ;

Localisation / Location

INIST-CNRS, Cote INIST : 21224, 35400011411361.0070